Seeking Alpha Article (not sure if printed yet on this board)
Newly Formed Marker Therapeutics ( MRKR ) Is A Treasure Yet To Be Discovered By Wall Street Analysts
Oct. 18, 2018 7:12 AM ET
Summary
•Marker Therapeutics ( MRKR ) is a joint merger issued from former Tapimmune and unknown private Marker .
•MRKR has deep value hidden in P1 data unknown by most analysts.
•Dream Team Scientists on board.
•Wide cancer applications.
•MRKR to become major player in upcoming $ 100BB immunology market.
Newly formed Marker Therapeutics (NASDAQ:MRKR) is a treasure yet to be discovered by Wall Street analysts .
At today's ( 10/17/18 ) introduction price of $8,40 and valuation of +/- $575M with fully diluted count of 68.5M shares, it is completely de-risked and will soon find its true value .
So, what could be MRKR's true value today ?
In NOV2015, KITE published its CAR-T P1 report and saw its market cap balloon to $3,2 BB from its original IPO of $ 626MM .
This valuation was for a single type of engineered T-cell ! .
Gilead later purchased KITE in AUG2018 or a whopping $ 11,9BB and it rests to be seen how they will capitalise on this acquisition.
MRKR 's Multi Tumor-Associated Antigen ( Multi-TAA ) cell therapy is polyclonal and expands around 4000 different T cells, each possessing anti-tumoral properties and each recognised as a part of the body's immune system with no cytokine reaction or immune rejection.
Therefore, I contend that MRKR's valuation right now is at the very least, if not more, valuable than KITE's P1 data and therefore should be around $ 50/share vs today's introduction of $8,4 at the closing of the Bell.
This price discounts completely the value of Tapimmune that has a promising pipeline of important vaccines under various phases of progress, some of which to be published before 2018 year's end .
MRKR P2 results will be published between NOV19-MAR20 and should be highly reflective of the successful P1 .
MRKR's value is multi-folded :
1. MRKR recently uncovered P1 data beats the competion : KITE/JUNO/Celectis/Adaptimmune/Novartis because its technology is Multi-Specific, has Epitope spreading,has no gene modification, never had a fatality caused by its therapy, does not require Lymphodepletion.
2. MRKR has the DREAM TEAM in Immunology research with Prof.James P. Allison,Ph.D., the " father of Immunotherapy ", 2018 Medecine Nobel Price Winner and a member of its Scientific Advisory Board.
3.MRKR's Multi-antigen targeting approach with demonstrated overwhelming results in their P1 is about 40 times cheaper than current CAR-t competitors .
4.MRKR's technology has a much simpler approach for the patient and does not require a hospital stay.
5.MRKR's technology has a much simpler manufacturing process thus lower cost and is scalable.
In conclusion to this short introduction, I urge you to do due diligence by researching all you can on Marker Therapeutics before you make an investment decision.
My conclusion, and I'll leave it at that, is that Marker Therapeutics solution will soon be an important part of many cancer therapies and will save millions of lives .
We live in exciting times , a paradigm shift of some sort, as scientific discoveries are finding their way to solve and even cure human diseases that we could only dream of in the recent past.
Marker Therapeutics will be a part of the solution.
I am / We are LONG on MRKR
Disclosure: I am/we are long MRKR.
SeekingAlpha
Like this post
